News|Articles|March 5, 2026

Eli Lilly Launches Employer Connect Platform Offering Obesity Coverage Options

Listen

0:00 / 0:00

Key Takeaways

Employer Connect aggregates diverse administrators, from basic benefits management to comprehensive obesity programs with wraparound services, enabling employers to tailor coverage models to workforce needs and financial constraints.
Zepbound access is facilitated through a dedicated pharmacy network (eg, HealthDyne, CenterWell) with a $449 per-dose discounted acquisition price, while employer/employee spend varies by program design.
Obesity affects >100 million U.S. adults and drives >$1.7 trillion in annual economic impact, yet about half of commercially insured employees lack coverage for weight management medications.
The approach is positioned to shift treatment continuity from coverage-driven attrition toward medically indicated use by reducing cost barriers and improving benefit predictability.
LillyDirect remains a separate direct-to-consumer fulfillment and support channel (home delivery, savings cards, education, telehealth connections) spanning obesity, migraine, and diabetes.

Eli Lilly launches Employer Connect, a new platform linking employers with benefit administrators and a pharmacy network to expand affordable access to its obesity medication Zepbound for U.S. workers.

Eli Lilly has launched Employer Connect, a platform designed to expand access to obesity treatment for U.S. employees by giving employers flexible, cost-transparent options for covering weight management medications.

FDA to Take Action Against Mass-Marketing of Illegal Copycat Drugs: Report

Novo Nordisk Launches First Super Bowl Commercial for Wegovy Pill

Hims & Hers Pulls Access to Compounded Semaglutide Pill Following Controversial Launch

The platform builds off of the telehealth platform Lilly launched back in January 2024, LillyDirect, which aimed to sell drugs directly to consumers with a prescription, including its GLP-1 Zepbound.²

"By enabling coverage outside traditional benefit designs, we lower barriers to treatment and give employers greater control over how they support employee access to obesity care," said Kevin Hern, senior vice president, Eli Lilly and Company. "This innovation can help employees access authentic obesity management medicines with more affordable out-of-pocket costs."

What is Employer Connect?

The platform is designed to connect employers with upwards of fifteen independent program administrators and a dedicated pharmacy network, including dispensing pharmacies HealthDyne and CenterWell to help design benefits programs tailored to their workforce and budget.¹ The platform was designed to improve access to obesity care through reductions in cost barriers for employees, while also providing employers greater cost predictability and transparency.¹

Administrators range from those offering basic benefits administration to those providing comprehensive obesity care with wraparound support services. Through the platform, Lilly's Zepbound (tirzepatide) KwikPen will be available to network pharmacies at a discounted price of $449 for all doses, though final costs to employers and employees will vary based on the program administrator and cost-sharing model chosen.¹

What employers and administrators are already involved?

The platform launched with a broad range of program administrators including the following:

9amHealth
Calibrate Health
GoodRx
Mark Cuban Cost Plus Drug Company
Teladoc Health
Transcarent
Waltz Health
Andel
Crux Health
eMed
Flytehealth
SALTA Direct Primary Care
Sesame
Form Health

Why is employer coverage for obesity care a problem?

Obesity affects more than 100 million American adults and costs the U.S. economy over $1.7 trillion annually, including $480 billion in direct medical costs and $1.24 trillion in lost productivity.¹ Despite this, coverage for obesity medications remains inconsistent as roughly half of commercially insured employees currently lack covered access to weight management treatments.¹

Ilya Yuffa, executive vice president and president of Lilly USA, said the platform is designed to ensure that access to treatment is driven by medical need rather than coverage gaps. "For far too many people living with obesity, starting or staying on treatment isn't just a medical decision, it's an access decision driven by coverage and cost," he said.

Is this different from LillyDirect?

The platform is different from Lilly’s Direct-to-consumer program, LillyDirect Pharmacy Solutions, as LillyDirect allows patients to order prescribed Lilly medicines directly, with free home delivery fulfilled through third-party online pharmacy services.²

Patients using LillyDirect have access to Lilly's affordability programs and savings cards, which are automatically applied for eligible patients at checkout.² The platform also provides disease education resources, access to independent telehealth providers, and a search tool for patients who prefer to find in-person care near them. LillyDirect is available to patients’ managing obesity, migraine, and diabetes.²

Sources

Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients Eli Lilly and Company March 5, 2026 https://investor.lilly.com/news-releases/news-release-details/lilly-employer-connect-platform-launches-over-fifteen
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect Eli Lilly and Company January 4, 2024 https://investor.lilly.com/news-releases/news-release-details/lilly-launches-end-end-digital-healthcare-experience-through

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!